Blood Sugar Control and Risk for Hypoglycemia within Therapy of Type2 Diabetes with the New GLP-1 Receptor Agonist Liraglutide

作者：Kern W^*

来源：Diabetologie und Stoffwechsel, 2010, 5(5): 287-292.

DOI：10.1055/s-0030-1262593

• GLP-1 receptor agonists
• hypoglycemia
• human GLP-1 analogue
• liraglutide
• HbA(1c)

The most important aspect for the optimal choice of diabetes treatment is its capacity for effective glycemic control and a low risk of hypoglycemia. However, approximately 40-50% of patients do not reach the glycemic control target (HbA(1c) < 7%) with the currently available treatment options. One of the reasons for this is the fear of hypoglycemia which often occurs with conventional diabetes medications such as sulfonylurea and insulin. This fear entails a reluctance to initiate or intensify more effective therapies in a timely manner, resulting in prolonged periods of poor glycemic control. The new incretin-based therapy of type 2 diabetes (GLP-1-receptor agonists and DPP-4-inhibitors) avoids clinically relevant hypoglycaemia. Particularly, GLP-1-receptor agonists are advantageous in terms of glycemic control, reduction of body weight and beta-cell function, and are therefore a useful alternative treatment option to currently available therapies. Exenatide was the first approved GLP-1mimetic. Since July 2009, another GLP-1 receptor agonist, liraglutide, was launched in Germany. This article reviews results from the phase3 liraglutide study program (LEAD), with particular emphasis on hypoglycemia.

• 出版日期2010-10